Zacks Research Estimates Glaukos FY2028 Earnings

Glaukos Corporation (NYSE:GKOS) – Stock analysts at Zacks Research issued their FY2028 earnings estimates for shares of Glaukos in a research report issued to clients and investors on Monday, March 9th. Zacks Research analyst Team forecasts that the medical instruments supplier will post earnings of $1.68 per share for the year. The consensus estimate for Glaukos’ current full-year earnings is ($1.08) per share.

Glaukos (NYSE:GKOS) last issued its quarterly earnings data on Tuesday, February 17th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.06). The business had revenue of $143.12 million for the quarter, compared to the consensus estimate of $132.16 million. Glaukos had a negative net margin of 36.99% and a negative return on equity of 7.00%. The company’s revenue was up 35.6% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.40) EPS.

Several other brokerages have also recently issued reports on GKOS. UBS Group lifted their target price on Glaukos from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, December 23rd. Citigroup upped their price target on shares of Glaukos from $113.00 to $125.00 and gave the company a “buy” rating in a report on Thursday, December 11th. BTIG Research reiterated a “buy” rating and set a $131.00 target price on shares of Glaukos in a research report on Wednesday, February 18th. Wall Street Zen lowered Glaukos from a “buy” rating to a “hold” rating in a report on Saturday, February 21st. Finally, Piper Sandler reiterated an “overweight” rating and set a $165.00 target price on shares of Glaukos in a report on Wednesday, January 14th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $133.69.

Glaukos Stock Down 2.6%

NYSE GKOS opened at $103.05 on Tuesday. The company has a current ratio of 4.69, a quick ratio of 4.06 and a debt-to-equity ratio of 0.10. Glaukos has a 12 month low of $73.16 and a 12 month high of $130.23. The stock’s 50 day moving average is $115.41 and its 200 day moving average is $101.18. The stock has a market cap of $5.98 billion, a PE ratio of -31.61 and a beta of 0.70.

Insider Buying and Selling

In other news, COO Joseph E. Gilliam sold 10,498 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $127.68, for a total transaction of $1,340,384.64. Following the sale, the chief operating officer owned 92,366 shares of the company’s stock, valued at $11,793,290.88. This trade represents a 10.21% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Aimee S. Weisner sold 15,000 shares of the business’s stock in a transaction on Thursday, February 19th. The shares were sold at an average price of $117.38, for a total transaction of $1,760,700.00. Following the completion of the transaction, the director owned 18,806 shares of the company’s stock, valued at approximately $2,207,448.28. This represents a 44.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 320,000 shares of company stock worth $37,202,909. 6.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Glaukos

A number of institutional investors have recently modified their holdings of GKOS. Smartleaf Asset Management LLC raised its holdings in Glaukos by 9.7% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,383 shares of the medical instruments supplier’s stock worth $158,000 after purchasing an additional 122 shares during the period. Larson Financial Group LLC increased its position in shares of Glaukos by 62.0% in the fourth quarter. Larson Financial Group LLC now owns 345 shares of the medical instruments supplier’s stock valued at $39,000 after buying an additional 132 shares in the last quarter. CWM LLC raised its stake in shares of Glaukos by 25.2% during the 4th quarter. CWM LLC now owns 710 shares of the medical instruments supplier’s stock worth $80,000 after buying an additional 143 shares during the period. Commonwealth Equity Services LLC lifted its position in shares of Glaukos by 1.7% during the 4th quarter. Commonwealth Equity Services LLC now owns 8,383 shares of the medical instruments supplier’s stock valued at $947,000 after buying an additional 144 shares in the last quarter. Finally, Evergreen Capital Management LLC grew its stake in Glaukos by 4.3% in the 4th quarter. Evergreen Capital Management LLC now owns 3,549 shares of the medical instruments supplier’s stock valued at $401,000 after acquiring an additional 145 shares during the period. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Glaukos Company Profile

Glaukos Corporation is a medical technology company specializing in the development, manufacturing and commercialization of innovative therapies for patients with glaucoma and other chronic eye diseases. The company’s core offerings focus on micro-invasive glaucoma surgery (MIGS), designed to reduce intraocular pressure and manage glaucoma more safely and effectively than traditional surgical approaches. Glaukos’s flagship products include the iStent, iStent inject and iStent infinite trabecular micro-bypass stents, which are implanted during cataract surgery to improve aqueous outflow and help control eye pressure.

Beyond its MIGS portfolio, Glaukos has expanded into sustained drug-delivery solutions.